<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-22798" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Hepatobiliary Tract Cancer</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Lotfollahzadeh</surname>
            <given-names>Saran</given-names>
          </name>
          <aff>Vascular Reserach, Department of Medicine, Boston University School of Medicine, Boston, MA 02118, USA, Department of Surgery, vascular and endovascular surgery section, Boston Medical Center, Boston, MA</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Hoilat</surname>
            <given-names>Gilles J.</given-names>
          </name>
          <aff>University of Iowa Hospital &#x00026; Clinics</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Smith</surname>
            <given-names>Melinda</given-names>
          </name>
          <aff>West Virginia University</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Recio-Boiles</surname>
            <given-names>Alejandro</given-names>
          </name>
          <aff>University of Arizona</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Babiker</surname>
            <given-names>Hani M.</given-names>
          </name>
          <aff>University of Arizona Cancer Center</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Saran Lotfollahzadeh declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Gilles Hoilat declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Melinda Smith declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Alejandro Recio-Boiles declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Hani Babiker declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>3</day>
          <month>6</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-22798.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>In the past, the term cholangiocarcinoma was used to reference intrahepatic bile duct cancer. However, usage of the term has evolved and it is now used to reference intrahepatic, perihilar, and extrahepatic tumors of the bile tract such as hepatobiliary tract cancer. The gallbladder and ampulla of Vater are considered structures of the biliary tract system hence malignancies of those parts are usually included in research and publications involving cholangiocarcinoma. Cholangiocarcinoma remains a rare and highly lethal malignancy due to the characteristically locally advanced, unresectable stage upon diagnosis. This activity reviews the evaluation, treatment, and prognosis of hepatobiliary tract cancer and highlights the role of the interprofessional team in evaluating and improving care for patients with this condition.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Describe the population most at risk for developing hepatobiliary tract cancer.</p></list-item><list-item><p>Explain exam findings that should prompt consideration of hepatobiliary tract cancer.</p></list-item><list-item><p>Review the evaluation of hepatobiliary tract cancer.</p></list-item><list-item><p>Demonstrate interprofessional team strategies for improving care coordination to enhance outcomes for patients affected by hepatobiliary tract cancer.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=22798&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=22798">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-22798.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Cholangiocarcinoma&#x000a0;originally referred to intrahepatic bile duct cancer. However, the term currently&#x000a0;includes intrahepatic, perihilar, and extrahepatic tumors of the bile tract such as hepatobiliary tract cancer. The gallbladder and ampulla of Vater are considered structures of the biliary tract system hence malignancies of those parts are usually included in research and publications involving cholangiocarcinoma. Cholangiocarcinoma is a rare and highly lethal malignancy due to the locally advanced, unresectable stage at diagnosis.&#x000a0;<xref ref-type="bibr" rid="article-22798.r1">[1]</xref><xref ref-type="bibr" rid="article-22798.r2">[2]</xref></p>
      </sec>
      <sec id="article-22798.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>Chronic inflammation is associated with the risk of developing biliary tract cancer. The strongest correlation to develop cholangiocarcinoma is primary sclerosing cholangitis (PSC), a feature characteristic of inflammatory bowel disease, particularly ulcerative colitis. In addition, choledochal cyst, hepatolithiasis, and liver fluke are well-known risk factors for cholangiocarcinoma. Other associations for intrahepatic cholangiocarcinoma are chronic liver diseases such as cirrhosis due to hepatitis C virus (HCV), hepatitis B virus (HBV), metabolic syndrome, and alcoholic and non-alcoholic fatty liver disease. Thorotrast, a radiological contrast, was banned due to its carcinogenic potential with a strong association with cholangiocarcinoma. Cholangiocarcinoma has been described with Lynch syndrome and multiple biliary papillomatosis.<xref ref-type="bibr" rid="article-22798.r3">[3]</xref></p>
      </sec>
      <sec id="article-22798.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>Although cholangiocarcinoma represents 3% of all gastrointestinal malignancies, the United&#x000a0;States Cancer Statistics estimate 52,450 new cases and 32,750 expected death&#x000a0;cases by grouping liver, intrahepatic bile duct, gallbladder, and other biliary cancer. Collectively, this represents 6% of all new cancer sites, making it the fifth deadliest cancer. Intrahepatic, perihilar, and distal biliary tract cancers divided by anatomical site account for 5% to 10%, 50% to 60%, and 20% to 30% of cases, respectively. Cholangiocarcinoma incidence increases with age except in cases related to primary sclerosing cholangitis which manifests in younger patients and is slightly more common in males, excluding gallbladder cancer which has a female predominance.<xref ref-type="bibr" rid="article-22798.r4">[4]</xref></p>
      </sec>
      <sec id="article-22798.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>The current&#x000a0;hypothesis establishes that chronic inflammation of the bile duct tissue will accumulate successive genomic mutations that over the years will&#x000a0;lead to malignant transformation similar to other gastrointestinal cancers. Intraductal papillary neoplasm and intraepithelial neoplasia are well-known cholangiocarcinoma precursors, which may progress from pre-neoplastic&#x000a0;to carcinoma in situ and then into invasive&#x000a0;cancer while progressively harboring mutations in p53, SMAD4, CDK2A tumor suppressors and/or oncogenes <italic toggle="yes">RAS</italic>, <italic toggle="yes">BRAF</italic>, <italic toggle="yes">EGFR</italic>, and <italic toggle="yes">PIK3CA</italic>. Cholangiocarcinoma histopathology is adenocarcinoma in more than 90% of cases and, infrequently, squamous cell carcinoma. Intrahepatic carcinomas also&#x000a0;may&#x000a0;have a biphenotypic differentiation called hepatocholangiocarcinoma.&#x000a0;<xref ref-type="bibr" rid="article-22798.r5">[5]</xref></p>
      </sec>
      <sec id="article-22798.s6" sec-type="Histopathology">
        <title>Histopathology</title>
        <p>Histologically, intrahepatic cholangiocarcinoma usually consists of penetrating well-formed or cribriform glands &#x000a0;in an ample fibrous stroma</p>
      </sec>
      <sec id="article-22798.s7" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>Bile duct obstruction symptoms include jaundice; abdominal pain,&#x000a0;particularly in the right upper quadrant; clay-colored stools; cola-colored urine; and skin pruritus which are common presentations of extrahepatic cholangiocarcinoma. Patients can present with&#x000a0;unspecific symptoms of advanced&#x000a0;malignancy&#x000a0;including fever, night sweats, weight loss, and general malaise. Acute cholangitis is a rare presentation. Intrahepatic cholangiocarcinoma may present differently with a more obscure scenario, such as an abnormal laboratory finding or a lesion detected incidentally on imaging in an otherwise asymptomatic patient during hepatocellular carcinoma (HCC) screening for liver disease.</p>
        <p>Physical examination may demonstrate jaundice, right upper quadrant pain, hepatomegaly, or&#x000a0;Courvoisier sign with a palpable non-tender gallbladder which&#x000a0;is more likely to develop due to a chronic progressive malignant obstruction rather than an intermittent benign obstruction.<xref ref-type="bibr" rid="article-22798.r6">[6]</xref><xref ref-type="bibr" rid="article-22798.r7">[7]</xref></p>
      </sec>
      <sec id="article-22798.s8" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>Patients, particularly those with obstructive jaundice or right upper quadrant pain, will require complete blood count, basic chemistry panel, and liver function tests. Results may reveal an initial, unspecific cholestatic pattern caused by bile obstruction that may lead to hepatocellular injury.</p>
        <p>Ultrasonography (US) and CT are the usual initial imaging for jaundiced patients and provide information on the location and anatomy of the lesion. CT scans performed for intrahepatic lesions have limitations in discriminating benign from malignant lesions, but dynamic magnetic resonance (MR) and MR cholangiopancreatography can provide the disease extent more accurately and better distinguish intrahepatic cholangiocarcinoma from hepatocellular carcinoma and biphenotypic carcinomas. Obtaining either intrahepatic or perihilar tissue for diagnosis may be challenging. Endoscopic ultrasound or endoscopic retrograde cholangiopancreatography are preferred modalities for extrahepatic obstruction because it allows direct bile duct visualization, diagnostic biopsy, and therapeutic interventions such as stent placement. Primary sclerosing cholangitis-associated cholangiocarcinoma can be challenging.</p>
        <p>Tumor markers including carcinoembryonic antigen, alpha-fetoprotein, and carbohydrate antigen 19-9 are frequently collected to differentiate suspicious intrahepatic lesions. Elevated alpha-fetoprotein (AFP) may support hepatocellular carcinoma&#x000a0;particularly those with liver disease and CA 19-9 for cholangiocarcinoma in the appropriate clinical scenario. Biphenotypic carcinomas may show AFP elevation. Ca 19-9 greater than 129 unit/mL, CEA greater than 5.2 ng/mL, and low IgG4 can support a cholangiocarcinoma diagnosis, particularly in patients with primary sclerosing cholangitis. A tumor markers baseline test is potentially useful for therapy monitoring and surveillance for recurrence of the disease. CA 19-9 on concentrations of hundreds of units/mL are consistent with advanced disease and poor prognosis.</p>
        <p>Initial staging workup may include CT chest, abdomen, and pelvis if not previously obtained. If no metastatic disease is evident&#x000a0;and the patient is being considered for surgical resection, occasionally positron emission&#x000a0;tomography/CT can be ordered to evaluate for an occult disease which can prevent a morbid surgery. Surgical candidates will proceed with diagnostic laparoscopy before resection.</p>
        <p>An American Joint&#x000a0;Committee&#x000a0;on Cancer and Union for International Cancer Control 2017 group separated the staging systems of cholangiocarcinoma depending on whether the location of the bile duct cancer is perihilar, distal, or intrahepatic. Each was differentiated on tumor size (T) designation and 5-year overall survival prognosis accordingly. On a multi-institutional analysis of intrahepatic cholangiocarcinoma, the 5-year survival rate was higher for those patients without multiple tumors or vascular invasion and nodal disease on surgical pathology specimen evaluation.&#x000a0;<xref ref-type="bibr" rid="article-22798.r8">[8]</xref><xref ref-type="bibr" rid="article-22798.r9">[9]</xref><xref ref-type="bibr" rid="article-22798.r10">[10]</xref></p>
      </sec>
      <sec id="article-22798.s9" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>Neoadjuvant therapy is not considered a standard of care in cholangiocarcinoma. Rarely, locally advanced or borderline resectable cases may receive neoadjuvant chemotherapy or chemoradiation therapy based on low-powered studies. Orthotopic liver transplantation has been studied in selected populations with inconclusive results. Neoadjuvant therapy should be offered in a clinical trial setting.</p>
        <p>Surgery is the only curative treatment for selected patients. The surgical procedure differs according to the anatomical location. Distal lesions are treated with pancreaticoduodenectomy, the Whipple procedure. Intrahepatic lesions will require hepatectomy, and lymphadenectomy is rarely performed. For hilar lesions, surgical resection will vary according to the Bismuth-Corlette anatomical classification.&#x000a0;</p>
        <p>Type I Bismuth-Corlette can involve the extrahepatic bile ducts but not the biliary confluence and can be treated with biliary surgical resection/Whipple procedure.&#x000a0;Type II involves an En bloc resection of the extrahepatic bile ducts, cholecystectomy, and hepatoduodenal ligament lymph node resection, with the creation of a Roux-en-Y hepaticojejunostomy. Type III (Type a and b) involves radical resection of the extrahepatic duct, with ipsilateral hepatic lobectomy, hepatoduodenal ligament lymph node resection, and a Roux-en-Y hepaticojejunostomy (Type III a require right hepatectomy or trisegmentectomy and Type IIIb requires a left hepatectomy). Type IV is predominately unresectable.<xref ref-type="bibr" rid="article-22798.r11">[11]</xref>&#x000a0;</p>
        <p>Postoperative therapy should be&#x000a0;offered&#x000a0;within 8 to 12 weeks and&#x000a0;requires&#x000a0;baseline laboratory&#x000a0;and imaging before therapy initiation.</p>
        <p>Adjuvant therapy should be&#x000a0;offered&#x000a0;to patients&#x000a0;with a resected pathological&#x000a0;specimen and a report of vascular invasion, node positivity, and positive margins, and preferably, concurrent adjuvant chemoradiation or adjuvant chemotherapy alone should be offered. There is limited clinical trial data to define the standard of care, and enrollment in a clinical trial is encouraged.</p>
        <p>The National Comprehensive Cancer Network (NCCN) consensus-based adjuvant guidelines recommend&#x000a0;the following<xref ref-type="bibr" rid="article-22798.r12">[12]</xref>:</p>
        <p>
<bold>Extrahepatic Cholangiocarcinoma with Negative Margins and Negative Nodes</bold>
</p>
        <p>Chemotherapy&#x000a0;alone for 6 months with gemcitabine (Gem) [1000 mg/m2 weekly for 3 of every 4 weeks] or fluoropyrimidine (5-FU) [leucovorin 20 mg/m2 followed by FU 425 mg/m2 intravenous [IV] bolus days 1 through 5, every 28 days] published in the ESPAC-3 Trial which enrolled 96 patients with bile duct cancer, and the median overall survival (mOS) for the&#x000a0;chemotherapy&#x000a0;group was 43.1 months versus 35.2 months in the observation group, albeit not statistically significant. Alternatively, 5-FU [225 mg/m2 daily]-based&#x000a0;adjuvant chemoradiation&#x000a0;from other gastrointestinal malignancy extrapolation data from the rectal cancer experience.&#x000a0;<xref ref-type="bibr" rid="article-22798.r13">[13]</xref></p>
        <p>
<bold>Extrahepatic Cholangiocarcinoma with Positive Margins, Invasive Disease, or Carcinoma in Situ at the Margin&#x000a0;</bold>
</p>
        <p>Four cycles of Capecitabine (Cap) [1500 mg/m(2) per day on days 1 to 14] plus Gemcitabine (Gem) [1000 mg/m(2) intravenously on days 1 and 8], every 21 days followed by 5-FU CRT [Cap 1330 mg/m2 per day divided into two daily doses and RT 45 Gy to regional lymphatics; 54 to 59.4 Gy to tumor bed] published in a single-arm SWOG-S0809 trial enrolled 54 bile duct cancer and showed a mOS of 35 months without a comparison group.</p>
        <p>
<bold>Intrahepatic Cholangiocarcinoma with Negative Disease</bold>
</p>
        <p>No recommendations.</p>
        <p>
<bold>Positive Margins&#x000a0;</bold>
</p>
        <p>Consider re-resection, ablation, 5-FU or Gemcitabine chemotherapy, or&#x000a0;chemoradiation therapy&#x000a0;discussion with a multidisciplinary team.</p>
        <p>At ASCO 2017, BILCAP study was presented as first phase 3 randomized adjuvant therapy for patients with no postsurgical complications and Eastern Cooperative&#x000a0;Oncological&#x000a0;Group of two or less (ECOG less than 2), 447 patients were randomized 1:1 Cap N 223[1250 mg/m2 D1-14, every 21 days, for eight cycles] or observation (Obs) N224 from 44 UK sites 2006 through 2014, it included 19% Intrahepatic, 28% hilar, 35% extrahepatic bile duct cancer and results showed an&#x000a0;mOS for Cap 53mo when compared to Obs 36mo (HR 0.75 p0.028). Cap soon will be adopted as the new standard of care.</p>
        <p>Surveillance by&#x000a0;NCCN recommendations includes imaging every 6 months for 2 years if clinically indicated, then annually up to 5 years. The oncologist&#x000a0;may monitor&#x000a0;patients closely&#x000a0;with liver function tests and tumor markers (CEA and CA19-9) every 3 to 4 months for 2 years, then every 6 months up to 5 years. All above-mentioned tests can&#x000a0;be performed&#x000a0;when clinically indicated.</p>
        <p>No single or combined therapy in unresectable, locally advanced, and metastatic cholangiocarcinoma will achieve a cure; rather the focus is on palliative intervention and extension of survival. All patients with advanced and&#x000a0;unresectable disease should be&#x000a0;offered a clinical trial when feasible. Patients with good performance status (ECOG 0-1) for chemotherapy could consider first-line option Gem [1000 mg/m2] plus Cisplatin (Cis) [25 mg/m2] on days one and eight every three weeks with acceptable toxicity in low dose cis as published in ABC-02 randomized phase 2 study which included 242 metastatic bile duct cancer patients and showed a mOS of 11.7 months in the combination arm when compared to 8.3 months of Gem alone (HR, 0.70; p0.002).&#x000a0;Other&#x000a0;first-line, gem-based combinations are not&#x000a0;randomized studies and have reported a mOS for GemCap&#x000a0;12.7 months and Gem with&#x000a0;Oxaliplatin&#x000a0;14.3 months both on a selected population of patients. Alternative 5-FU-based combination plus Cis 11.5 months or&#x000a0;Cap&#x000a0;11.3 months. Patients with poor performance may receive oral&#x000a0;Cap which reported a mOS of 8.1 months when compared to the best&#x000a0;supportive care of 4.5 months. Future clinical trials with targeted therapy, including FGFR, MEK, and other drugs tailored per the tumor molecular profile, are ongoing and preliminary reports are promising.&#x000a0;<xref ref-type="bibr" rid="article-22798.r14">[14]</xref><xref ref-type="bibr" rid="article-22798.r15">[15]</xref></p>
      </sec>
      <sec id="article-22798.s10" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <list list-type="bullet">
          <list-item>
            <p>Primary sclerosing cholangitis</p>
          </list-item>
          <list-item>
            <p>Secondary sclerosing cholangitis&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Recurrent pyogenic cholangitis&#x000a0;</p>
          </list-item>
          <list-item>
            <p>AIDS-associated cholangiopathy</p>
          </list-item>
          <list-item>
            <p>Autoimmune pancreatitis-cholangitis syndrome&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Hepatobiliary inflammatory pseudotumor&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Mirizzi Syndrome&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Xanthogranulomatous cholecystitis or cholangitis</p>
          </list-item>
          <list-item>
            <p>Biliary sarcoidosis&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Chemotherapy-induced biliary sclerosis&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Intrabiliary metastasis&#x000a0;</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-22798.s11" sec-type="Surgical Oncology">
        <title>Surgical Oncology</title>
        <p>Surgery is the only curative treatment for selected patients. The surgical procedure differs according to the anatomical location. Distal lesions are treated with pancreaticoduodenectomy, the Whipple procedure. Intrahepatic lesions will require hepatectomy, and lymphadenectomy is rarely performed. For hilar lesions, surgical resection will vary according to the Bismuth-Corlette anatomical classification.</p>
      </sec>
      <sec id="article-22798.s12" sec-type="Radiation Oncology">
        <title>Radiation Oncology</title>
        <p>The addition of radiotherapy has been associated with an improvement in survival rate in older patients with nonmetastatic biliary tract tumors. Several studies showed that there was an increase in the median survival duration in patients undergoing radiation postoperatively&#x000a0;</p>
      </sec>
      <sec id="article-22798.s13" sec-type="Staging">
        <title>Staging</title>
        <p>Staging follows the TNM system and is described in detail in table 1.&#x000a0;For hilar lesions, staging for surgical resection will vary according to the Bismuth-Corlette anatomical classification.</p>
      </sec>
      <sec id="article-22798.s14" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>Prognosis depends on the location of the tumor as well as the stage of the tumor</p>
        <p>For intrahepatic bile duct tumors, the 5-year survival is as follows&#x000a0;</p>
        <list list-type="bullet">
          <list-item>
            <p>Localized tumor or stage I: 15%</p>
          </list-item>
          <list-item>
            <p>Regional spreading of the tumor seen in Stage II and III: 6%</p>
          </list-item>
          <list-item>
            <p>Distant metastasis or stage IV: 2%</p>
          </list-item>
        </list>
        <p>For Extrahepatic bile duct tumors, the 5-year survival is as follows&#x000a0;</p>
        <list list-type="bullet">
          <list-item>
            <p>Localized tumor or stage I: 30%</p>
          </list-item>
          <list-item>
            <p>Regional spreading of the tumor seen in Stage II and III: 24%</p>
          </list-item>
          <list-item>
            <p>Distant metastasis or stage IV: 2%</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-22798.s15" sec-type="Complications">
        <title>Complications</title>
        <p>Bile obstruction caused by the cancer can lead to infections , cholangitis , sepsis ,septic shock and death.&#x000a0;</p>
        <p>Other complication to keepin mind are the ones related to surgery , chemotherapy and radiotherapy.</p>
      </sec>
      <sec id="article-22798.s16" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>Biliary cancers have been associated with cirrhosis. Many causes of cirrhosis can be prevented such as excess alcohol intake, Infections with hepatitis B, and C among others. It is important to avoid the use of IV drug, excessive alcohol intake, and practice safe sexual relationships. A patient diagnosed with cancer should know that a multidisciplinary team involving multiple subspecialties is following the case. Keeping appointments, chemotherapy, radiotherapy sessions is crucial for a better outcome and survival. &#x000a0;&#x000a0;</p>
      </sec>
      <sec id="article-22798.s17" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Bile duct carcinoma is very difficult to diagnose as it may present with similar symptoms to gallstones including obstructive symptoms such as jaundice; abdominal pain; clay-colored stools; cola-colored urine; and skin pruritus. Patients can also present with unspecific symptoms of advanced malignancy including fever, night sweats, weight loss, and general malaise. The healthcare team needs to be diligent in considering the possibility of this deadly form of cancer and always include it as a possibility when evaluating patients with presentations of gallbladder disease. an interprofessional team approach of nurses, pharmacists, and physicians will provide the best possible results. [Level V]</p>
      </sec>
      <sec id="article-22798.s18">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=22798&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=22798">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/cancer/hepatobiliary-tract-cancer/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=22798">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/22798/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=22798">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <floats-group id="article-22798.s19">
        <fig id="article-22798.image.f1" position="float" orientation="portrait">
          <caption>
            <p>Cholangiocarcinoma. Coronal T2 Haste, Axial T2 Haste, and 60- and 10-minute post-contrast T1 Vibe images are submitted. A delayed enhancing hilar mass biopsy has proven to be cholangiocarcinoma. This mass has an increased T2 signal in comparison to the background liver parenchyma. Contributed by M Smith, MD</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="cb__cholangio__hilar" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <floats-group id="article-22798.s20">
        <fig id="article-22798.image.f2" position="float" orientation="portrait">
          <caption>
            <p>Axial T2 Haste and 20s, 3-minute, and 10-minute Post-Contrast. Axial T2 Haste and 20s, 3-minute, and 10-minute post-contrast T1 Vibe images are submitted. There is a delayed-enhancing mass in segment 7 of the right hepatic lobe, which biopsy has proven to be cholangiocarcinoma. This mass has increased T2 signal in comparison to the background liver parenchyma. Contributed by M Smith, MD</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="LB__cholangio2" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <floats-group id="article-22798.s21">
        <fig id="article-22798.image.f3" position="float" orientation="portrait">
          <caption>
            <p>Axial T2 Haste, Pre T1 Vibe, and 20 second and 3 minute post contrast T1 Vibe images are submitted. There is a delayed enhancing mass in the right hepatic lobe which is biopsy proven to be cholangiocarcinoma. This mass has increased T2 signal in comparison to the background liver parenchyma with decreased T1 signal also identified. Contributed by Melinda Smith, West Virginia University</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="LS__cholangio" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <floats-group id="article-22798.s22">
        <fig id="article-22798.image.f4" position="float" orientation="portrait">
          <caption>
            <p>Cholangiocarcinoma. Axial T2 Haste, 20s, and 3-minute post-contrast T1 Vibe images are submitted. There is marked biliary dilatation, greatest in the left biliary tree. A delayed enhancing hilar mass is identified, which is biopsy proven to be cholangiocarcinoma. This mass has increased T2 signal in comparison to the background liver parenchyma. Mild capsular retraction in the right hepatic lobe is noted. Contributed by M Smith, MD</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="NJ__cholangio__hilar" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <floats-group id="article-22798.s23">
        <fig id="article-22798.image.f5" position="float" orientation="portrait">
          <caption>
            <p>Staging of extrahepatic bile duct cancer. Adapted from American Joint Commission on Cancer staging 6th edition</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="Table__1" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <ref-list id="article-22798.s24">
        <title>References</title>
        <ref id="article-22798.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Siegel</surname>
                <given-names>RL</given-names>
              </name>
              <name>
                <surname>Miller</surname>
                <given-names>KD</given-names>
              </name>
              <name>
                <surname>Jemal</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Cancer Statistics, 2017.</article-title>
            <source>CA Cancer J Clin</source>
            <year>2017</year>
            <month>Jan</month>
            <volume>67</volume>
            <issue>1</issue>
            <fpage>7</fpage>
            <page-range>7-30</page-range>
            <pub-id pub-id-type="pmid">28055103</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22798.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>de Groen</surname>
                <given-names>PC</given-names>
              </name>
              <name>
                <surname>Gores</surname>
                <given-names>GJ</given-names>
              </name>
              <name>
                <surname>LaRusso</surname>
                <given-names>NF</given-names>
              </name>
              <name>
                <surname>Gunderson</surname>
                <given-names>LL</given-names>
              </name>
              <name>
                <surname>Nagorney</surname>
                <given-names>DM</given-names>
              </name>
            </person-group>
            <article-title>Biliary tract cancers.</article-title>
            <source>N Engl J Med</source>
            <year>1999</year>
            <month>Oct</month>
            <day>28</day>
            <volume>341</volume>
            <issue>18</issue>
            <fpage>1368</fpage>
            <page-range>1368-78</page-range>
            <pub-id pub-id-type="pmid">10536130</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22798.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chapman</surname>
                <given-names>RW</given-names>
              </name>
            </person-group>
            <article-title>Risk factors for biliary tract carcinogenesis.</article-title>
            <source>Ann Oncol</source>
            <year>1999</year>
            <volume>10 Suppl 4</volume>
            <fpage>308</fpage>
            <page-range>308-11</page-range>
            <pub-id pub-id-type="pmid">10436847</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22798.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Okuda</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Nakanuma</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Miyazaki</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Cholangiocarcinoma: recent progress. Part 1: epidemiology and etiology.</article-title>
            <source>J Gastroenterol Hepatol</source>
            <year>2002</year>
            <month>Oct</month>
            <volume>17</volume>
            <issue>10</issue>
            <fpage>1049</fpage>
            <page-range>1049-55</page-range>
            <pub-id pub-id-type="pmid">12201863</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22798.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zen</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Adsay</surname>
                <given-names>NV</given-names>
              </name>
              <name>
                <surname>Bardadin</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Colombari</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Ferrell</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Haga</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Hong</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Hytiroglou</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Kl&#x000f6;ppel</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Lauwers</surname>
                <given-names>GY</given-names>
              </name>
              <name>
                <surname>van Leeuwen</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Notohara</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Oshima</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Quaglia</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Sasaki</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Sessa</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Suriawinata</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Tsui</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Atomi</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Nakanuma</surname>
                <given-names>Y</given-names>
              </name>
            </person-group>
            <article-title>Biliary intraepithelial neoplasia: an international interobserver agreement study and proposal for diagnostic criteria.</article-title>
            <source>Mod Pathol</source>
            <year>2007</year>
            <month>Jun</month>
            <volume>20</volume>
            <issue>6</issue>
            <fpage>701</fpage>
            <page-range>701-9</page-range>
            <pub-id pub-id-type="pmid">17431410</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22798.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chen</surname>
                <given-names>MF</given-names>
              </name>
            </person-group>
            <article-title>Peripheral cholangiocarcinoma (cholangiocellular carcinoma): clinical features, diagnosis and treatment.</article-title>
            <source>J Gastroenterol Hepatol</source>
            <year>1999</year>
            <month>Dec</month>
            <volume>14</volume>
            <issue>12</issue>
            <fpage>1144</fpage>
            <page-range>1144-9</page-range>
            <pub-id pub-id-type="pmid">10634149</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22798.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nehls</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Gregor</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Klump</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Serum and bile markers for cholangiocarcinoma.</article-title>
            <source>Semin Liver Dis</source>
            <year>2004</year>
            <month>May</month>
            <volume>24</volume>
            <issue>2</issue>
            <fpage>139</fpage>
            <page-range>139-54</page-range>
            <pub-id pub-id-type="pmid">15192787</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22798.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>de Jong</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Nathan</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Sotiropoulos</surname>
                <given-names>GC</given-names>
              </name>
              <name>
                <surname>Paul</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Alexandrescu</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Marques</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Pulitano</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Barroso</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Clary</surname>
                <given-names>BM</given-names>
              </name>
              <name>
                <surname>Aldrighetti</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Ferrone</surname>
                <given-names>CR</given-names>
              </name>
              <name>
                <surname>Zhu</surname>
                <given-names>AX</given-names>
              </name>
              <name>
                <surname>Bauer</surname>
                <given-names>TW</given-names>
              </name>
              <name>
                <surname>Walters</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Gamblin</surname>
                <given-names>TC</given-names>
              </name>
              <name>
                <surname>Nguyen</surname>
                <given-names>KT</given-names>
              </name>
              <name>
                <surname>Turley</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Popescu</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Hubert</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Meyer</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Schulick</surname>
                <given-names>RD</given-names>
              </name>
              <name>
                <surname>Choti</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Gigot</surname>
                <given-names>JF</given-names>
              </name>
              <name>
                <surname>Mentha</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Pawlik</surname>
                <given-names>TM</given-names>
              </name>
            </person-group>
            <article-title>Intrahepatic cholangiocarcinoma: an international multi-institutional analysis of prognostic factors and lymph node assessment.</article-title>
            <source>J Clin Oncol</source>
            <year>2011</year>
            <month>Aug</month>
            <day>10</day>
            <volume>29</volume>
            <issue>23</issue>
            <fpage>3140</fpage>
            <page-range>3140-5</page-range>
            <pub-id pub-id-type="pmid">21730269</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22798.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gore</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Shelhamer</surname>
                <given-names>RP</given-names>
              </name>
            </person-group>
            <article-title>Biliary tract neoplasms: diagnosis and staging.</article-title>
            <source>Cancer Imaging</source>
            <year>2007</year>
            <month>Oct</month>
            <day>01</day>
            <volume>7 Spec No A</volume>
            <issue>Special issue A</issue>
            <fpage>S15</fpage>
            <page-range>S15-23</page-range>
            <pub-id pub-id-type="pmid">17921093</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22798.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Malaguarnera</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Paladina</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Giordano</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Malaguarnera</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Bertino</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Berretta</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Serum markers of intrahepatic cholangiocarcinoma.</article-title>
            <source>Dis Markers</source>
            <year>2013</year>
            <volume>34</volume>
            <issue>4</issue>
            <fpage>219</fpage>
            <page-range>219-28</page-range>
            <pub-id pub-id-type="pmid">23396291</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22798.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Itri</surname>
                <given-names>JN</given-names>
              </name>
              <name>
                <surname>de Lange</surname>
                <given-names>EE</given-names>
              </name>
            </person-group>
            <article-title>Extrahepatic Cholangiocarcinoma: What the Surgeon Needs to Know RadioGraphics Fundamentals | Online Presentation.</article-title>
            <source>Radiographics</source>
            <year>2018</year>
            <season>Nov-Dec</season>
            <volume>38</volume>
            <issue>7</issue>
            <fpage>2019</fpage>
            <page-range>2019-2020</page-range>
            <pub-id pub-id-type="pmid">30422766</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22798.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Benson</surname>
                <given-names>AB</given-names>
              </name>
              <name>
                <surname>D'Angelica</surname>
                <given-names>MI</given-names>
              </name>
              <name>
                <surname>Abbott</surname>
                <given-names>DE</given-names>
              </name>
              <name>
                <surname>Abrams</surname>
                <given-names>TA</given-names>
              </name>
              <name>
                <surname>Alberts</surname>
                <given-names>SR</given-names>
              </name>
              <name>
                <surname>Saenz</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Are</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Brown</surname>
                <given-names>DB</given-names>
              </name>
              <name>
                <surname>Chang</surname>
                <given-names>DT</given-names>
              </name>
              <name>
                <surname>Covey</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Hawkins</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Iyer</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Jacob</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Karachristos</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kelley</surname>
                <given-names>RK</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Palta</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Park</surname>
                <given-names>JO</given-names>
              </name>
              <name>
                <surname>Sahai</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Schefter</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Schmidt</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Sicklick</surname>
                <given-names>JK</given-names>
              </name>
              <name>
                <surname>Singh</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Sohal</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Stein</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Tian</surname>
                <given-names>GG</given-names>
              </name>
              <name>
                <surname>Vauthey</surname>
                <given-names>JN</given-names>
              </name>
              <name>
                <surname>Venook</surname>
                <given-names>AP</given-names>
              </name>
              <name>
                <surname>Zhu</surname>
                <given-names>AX</given-names>
              </name>
              <name>
                <surname>Hoffmann</surname>
                <given-names>KG</given-names>
              </name>
              <name>
                <surname>Darlow</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>NCCN Guidelines Insights: Hepatobiliary Cancers, Version 1.2017.</article-title>
            <source>J Natl Compr Canc Netw</source>
            <year>2017</year>
            <month>May</month>
            <volume>15</volume>
            <issue>5</issue>
            <fpage>563</fpage>
            <page-range>563-573</page-range>
            <pub-id pub-id-type="pmid">28476736</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22798.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Valle</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Wasan</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Palmer</surname>
                <given-names>DH</given-names>
              </name>
              <name>
                <surname>Cunningham</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Anthoney</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Maraveyas</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Madhusudan</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Iveson</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Hughes</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Pereira</surname>
                <given-names>SP</given-names>
              </name>
              <name>
                <surname>Roughton</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Bridgewater</surname>
                <given-names>J</given-names>
              </name>
              <collab>ABC-02 Trial Investigators</collab>
            </person-group>
            <article-title>Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer.</article-title>
            <source>N Engl J Med</source>
            <year>2010</year>
            <month>Apr</month>
            <day>08</day>
            <volume>362</volume>
            <issue>14</issue>
            <fpage>1273</fpage>
            <page-range>1273-81</page-range>
            <pub-id pub-id-type="pmid">20375404</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22798.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ben-Josef</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Guthrie</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>El-Khoueiry</surname>
                <given-names>AB</given-names>
              </name>
              <name>
                <surname>Corless</surname>
                <given-names>CL</given-names>
              </name>
              <name>
                <surname>Zalupski</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Lowy</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Thomas</surname>
                <given-names>CR</given-names>
              </name>
              <name>
                <surname>Alberts</surname>
                <given-names>SR</given-names>
              </name>
              <name>
                <surname>Dawson</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>Micetich</surname>
                <given-names>KC</given-names>
              </name>
              <name>
                <surname>Thomas</surname>
                <given-names>MB</given-names>
              </name>
              <name>
                <surname>Siegel</surname>
                <given-names>AB</given-names>
              </name>
              <name>
                <surname>Blanke</surname>
                <given-names>CD</given-names>
              </name>
            </person-group>
            <article-title>SWOG S0809: A Phase II Intergroup Trial of Adjuvant Capecitabine and Gemcitabine Followed by Radiotherapy and Concurrent Capecitabine in Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma.</article-title>
            <source>J Clin Oncol</source>
            <year>2015</year>
            <month>Aug</month>
            <day>20</day>
            <volume>33</volume>
            <issue>24</issue>
            <fpage>2617</fpage>
            <page-range>2617-22</page-range>
            <pub-id pub-id-type="pmid">25964250</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22798.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Neoptolemos</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Moore</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Cox</surname>
                <given-names>TF</given-names>
              </name>
              <name>
                <surname>Valle</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Palmer</surname>
                <given-names>DH</given-names>
              </name>
              <name>
                <surname>McDonald</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Carter</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Tebbutt</surname>
                <given-names>NC</given-names>
              </name>
              <name>
                <surname>Dervenis</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Glimelius</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Charnley</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Lacaine</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Scarfe</surname>
                <given-names>AG</given-names>
              </name>
              <name>
                <surname>Middleton</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Anthoney</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ghaneh</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Halloran</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Lerch</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Ol&#x000e1;h</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Rawcliffe</surname>
                <given-names>CL</given-names>
              </name>
              <name>
                <surname>Verbeke</surname>
                <given-names>CS</given-names>
              </name>
              <name>
                <surname>Campbell</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>B&#x000fc;chler</surname>
                <given-names>MW</given-names>
              </name>
              <collab>European Study Group for Pancreatic Cancer</collab>
            </person-group>
            <article-title>Effect of adjuvant chemotherapy with fluorouracil plus folinic acid or gemcitabine vs observation on survival in patients with resected periampullary adenocarcinoma: the ESPAC-3 periampullary cancer randomized trial.</article-title>
            <source>JAMA</source>
            <year>2012</year>
            <month>Jul</month>
            <day>11</day>
            <volume>308</volume>
            <issue>2</issue>
            <fpage>147</fpage>
            <page-range>147-56</page-range>
            <pub-id pub-id-type="pmid">22782416</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
